Cardiovascular effects of GLP‐1 and GLP‐1‐based therapies: implications for the cardiovascular continuum in diabetes?
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Diabet. Med. 30, 289–299 (2013) Aims Glucagon‐like peptide‐1 receptor agonists and inhibitors of dipeptidyl peptidase‐4 that increase glucagon‐like peptide‐1 plasma concentrations are current treatment options for patients with diabetes mellitus. As patients with diabetes are a high‐risk population for the development of a severe and diffuse atherosclerosis, we aim to review the potential action of these drugs on cardiovascular disease and to summarize the potential role of present glucagon‐like peptide‐1‐based therapies from a cardiologist’s point of view. Methods Using a PubMed/MEDLINE search without language restriction, studies were identified and evaluated in order to review the effects of glucagon‐like peptide‐1‐based therapy on different stages of the cardiovascular continuum. Results Recent experimental as well as clinical data suggest that dipeptidyl peptidase‐4 inhibitors and glucagon‐like peptide‐1 receptor agonists—in addition to their metabolic effects—may have beneficial effects on the cardiovascular continuum at multiple stages, including: (1) cardiovascular risk factors; (2) molecular mechanisms involved in atherogenesis; (3) ischaemic heart disease; and (4) heart failure. Furthermore, retrospective analysis suggested decreased cardiovascular events in patients with glucagon‐like peptide‐1‐based therapies. Conclusion There are ample data to suggest beneficial effects of glucagon‐like peptide‐1‐based therapies on the cardiovascular continuum and large‐scale clinical trials are warranted to determine whether these effects translate into improved cardiovascular endpoints in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Malmberg, K., Rydén, L., Wedel, H., Birkeland, K., Bootsma, A., Dickstein, K., Efendic, S., Fisher, M., Hamsten, A., Herlitz, J., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi199 · Cited by 1,048
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654
Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429
Moretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350
Cited by
Balestrieri, M. L., Rizzo, M. R., Barbieri, M., Paolisso, P., D’Onofrio, N., Giovane, A., Siniscalchi, M., Minicucci, F., Sardu, C., D’Andrea, D., et al. (2015) · Diabetes · doi:10.2337/db14-1149 · Cited by 196
Rizzo, M., Rizvi, A. A., Patti, A. M., Nikolic, D., Giglio, R. V., Castellino, G., Li Volti, G., Caprio, M., Montalto, G., Provenzano, V., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0480-8 · Cited by 135
“blood pressure (BP) and plasma lipids [3], thus improving the cardio-metabolic profile of patients with T2DM [4, 5].”
BackgroundGLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
“For example, several clinical trials have shown that GLP-1 receptor agonists improve lipid profiles in patients with type 2 diabetes through reductions in LDL cholesterol, total cholesterol, triglyceride, and free fatty acid levels (40,47).”
BackgroundEffects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97
Metadata
- Authors
- Burgmaier, M., Heinrich, C., & Marx, N.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2013-02-20
- Volume
- 30
- Issue
- 3
- Pages
- 289-299
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W1514615788
- Cited by
- 40
- References
- 15
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular effects of GLP‐1 and GLP‐1‐based therapies: implications for the cardiovascular continuum in diabetes? https://app.cochat.ai/papers/10.1111/j.1464-5491.2012.03746.x
- The paper
- Burgmaier, M., Heinrich, C., & Marx, N. (2013). Cardiovascular effects of GLP‐1 and GLP‐1‐based therapies: implications for the cardiovascular continuum in diabetes? Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2012.03746.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.